Resources and Training for Regulatory Professionals
This article discusses the knowledge path for regulatory professionals from a career's early stages through specialization. It recommends a variety of ways to keep current on evolving regulatory issues, including on-the-job training, self-education via the Internet, attending conferences, networking, and membership in professional organizations.
Categories: Career Development, Regulatory intelligence, Features, Business and Leadership
Pharmaceutical Cleaning Processes
This article presents a lighthearted look at pharmaceutical industry cleaning processes, cleaning validation and cleaning verification.
Categories: Drugs, Features, FDA, WHO
Tags: Cleaning, Washing, Rinsing, Cleaning Validation
Ten Secrets to Regulatory Success
This article highlights "10 secrets to success" for regulatory professionals that may not be taught in formal regulatory affairs training programs, but practices the author learned "on the job." It includes suggestions for developing regulatory submissions and the importance of good writing, doing your "homework" and systematizing work procedures.
Categories: Career Development, Features, Communication
Regulatory Career Progression
This article discusses pathways for a career as a regulatory professional and possible career progression from junior to senior to managerial level. It summarizes the skills required for each level and what it takes to move up the corporate ladder. It also provides the responsibilities expected of a regulatory professional in a senior management position.
Categories: Career Development, Career Search, Features, Business and Leadership
Tags: Career Development, Regulatory Profession
FDA Inspections and Outcomes for Oral Solid Dosage (OSD) Manufacturing Facilities
The article discusses various types of current Good Manufacturing Practice (CGMP) inspections conducted by the US Food and Drug Administration (FDA) at oral solid dosage forms manufacturing facilities. It also elaborates on types of inspections, approaches to investigations, limitations of these inspections and major inspection outcomes in the event of deficiencies, including 483s, Warning Letters and Establishment Investigation Reports (EIRs).
Categories: Drugs, Compliance, Manufacturing, Features, US, FDA
Tags: Oral Solid Dosage, OSD, Inspections
Biological Products and Biosimilars: Global Naming Debate
This article presents the contrasting views and continuing debate among health authorities in Australia, Canada, Europe, Japan and the US as well as industry experts regarding conventions for naming biological products and biosimilars. It discusses the World Health Organization's (WHO's) proposal for naming and the importance of a clear distinction between the drugs to avoid confusion and ensure patient safety.
Categories: Biologics and biotechnology, Submission and registration, News, US, Canada, Europe, Asia, Oceania, FDA, EMA, Health Canada, PMDA, TGA, WHO
Tags: Biosimilars, Biosimilar Naming, Biological Qualifier, INN
Medicinal Product Registration in Egypt
This article provides an overview of Egypt's New Drug Application (NDA) procedure for imported brand pharmaceutical products, including new chemical entities and biologics. It discusses the various Egyptian Drug Authority (EDA) departments and the required procedures for moving products through registration and into the market.
Categories: Biologics and biotechnology, Drugs, Medical Devices, Submission and registration, Features
Tags: EDA, Egyptian Drug Authority
Identification of Medicinal Products (IDMP) Standards Part 4: Technical Approaches to IDMP
This article discusses IT approaches to support a gap analysis and implementation of the upcoming Identification of Medicinal Products (IDMP) standards with regard to generating, collecting and mapping accurate and correct data prior to submission in an effort to prevent delays in a product reaching the market.
Categories: Biologics and biotechnology, Drugs, Features, US, Europe, FDA, EMA, ISO
Tags: Identification of Medicinal Products, IDMP
Regulating Pediatric Studies: An EU and US Perspective
This article presents pediatric regulatory activities conducted by the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) and highlights global harmonization efforts, collaborative discussions and regulations for pediatric clinical trials.
Categories: Biologics and biotechnology, Drugs, Clinical, Features, US, Europe, FDA, EMA
Quality Certificates for Small Molecule Drug Product Applications for International Regulatory Submissions
This article provides a global overview of the general requirements and issues regulatory professionals may encounter while arranging for a variety of certificates for applications for small molecule drug products to be marketed internationally in the EU, US, Canada, Australia and Japan.
Categories: Drugs, Submission and registration, Features, US, Canada, Europe, Japan, Oceania, FDA, EMA, Health Canada, PMDA, TGA
Tags: Quality Certificates, eCTD, GMP
Conditional Approvals for Early Access to New Medications
This article provides insight into Conditional Approvals (CAs) and Conditional Marketing Approvals (CMAs) as developed across several jurisdictions to potentially provide earlier access to new medicines. The author explains the specifics regarding regulatory requirements for obtaining CAs in the European Union (EU), Japan and the US.
Categories: Biologics and biotechnology, Drugs, Regulatory strategy, Submission and registration, Features, US, Europe, Japan, FDA, EMA, PMDA, ICH
Tags: Conditional approval, Regenerative medicine
Navigating the Medical Device User Fee Act (MDUFA)
This article examines the benefits for both FDA and the medical device industry derived from "user fees" authorized by the passage of the Medical Device User Fee Act (MDUFA 2002) and its subsequent reauthorizations.
Categories: Medical Devices, Submission and registration, Features, US, CDRH
Tags: MDUFA, Medical Device User Fee Act, 510(k), PMA, User Fees
ICH Q12 Post Approval Change Management Protocol: Advantages for Consumers, Regulators and Industry
This article discusses the latest draft of ICH Q12 and significance of harmonizing regulatory requirements across regional borders. It emphasizes how Post-Approval Change Management Protocol (PACMP) can be used as a tool to improve strategic change management and ensure supply chain reliability.
Categories: Biologics and biotechnology, Drugs, Quality, Features, US, Europe, FDA, ICH
Tags: ICH Q12, Post Approval Change Management Protocol, Quality by Design, QbD
Generic Drug User Fee Act (GDUFA): Overview and Proposed Changes for 2018
This article discusses aspects of the Generic Drug User Fee Act enacted by Congress as part of the Food and Drug Administration Safety and Innovation Act (FDASIA), including fees, changes enabling FDA to speed up reviews, GDUFA goals and proposed changes and impacts as the first five–year phase concludes in 2017.
Categories: Generic drugs, Submission and registration, Features, US, FDA
Regulatory Harmonization Initiatives
This article provides an overview of global regulatory harmonization initiatives and addresses how various regulatory and other organizations are working toward improving access to medicinal products, such as pharmaceuticals and medical devices, and increasing quality through internationally harmonized inspection standards.
Categories: Biologics and biotechnology, Drugs, Medical Devices, Compliance, Features, US, Canada, Europe, Asia, Latin America and Caribbean, Africa, Middle East, Oceania, ICH, IMDRF, GHTF, APEC, OECD, WHO, ISO
FDA User Fee Programs
This article provides an overview of upcoming important changes to FDA's major user fee programs (PDUFA VI, MDUFA IV and GDUFA II) for Fiscal 2018–2022. It discusses new performance goals, additional commitments FDA has agreed upon with industry and how these changes could impact various types of industry submission strategies.
Categories: Biologics and biotechnology, Generic drugs, Medical Devices, Submission and registration, News, US, FDA
Tags: User Fees, PDUFA, MDUFA, GDUFA
Thailand's Approach to Drug Quality Assurance: Creation of the Green Book
This article discusses how Thailand's Ministry of Public Health (MOPH), Food and Drug Administration (Thai FDA) and a number of government and independent health agencies regulate drugs, both new and generic, as well as traditional, nonwestern medicines.
Categories: Drugs, Quality, Features, Asia
Tags: Thailand, Green Book, Quality Assurance
Identification of Medicinal Products (IDMP) Standards Part 3: Steps to Prepare for IDMP Implementation
This article discusses the gap analysis and preliminary activities necessary to prepare a pharmaceutical company for the upcoming IDMP standards; it is the final article in a three part series on the standards and their respective implementation guidelines. The first two articles presented reasons for the new standard, the driving forces behind IDMP, and the concepts behind the standard as well as the current timelines for introducing IDMP in worldwide markets.
Categories: Drugs, Features, FDA, EMA, ISO
The Prescription Drug User Fee Act (PDUFA): A Primer
This article discusses key points and benefits of the Prescription Drug User Fee Act (PDUFA) for those filing a New Drug Application (NDA) and explains how PDUFA user fees have played an important role in expediting FDA's drug approval process.
Categories: Biologics and biotechnology, Drugs, Submission and registration, News, US, FDA
Tags: User Fees, Prescription Drug User Fee Act, PDUFA
Impact of the Revised EU Clinical Trial Regulation
Clinical Trial Regulation EU No 536/2014 will come into effect in 2018. This article reports on aspects of the revised regulation and evaluates its potential impact on clinical trials conducted to assess medicinal products for human use. It discusses changes impacting the critical role of the Ethics Committees in the approval process for clinical trials as well as the planned, centralized data reporting channel, referred to as "the portal." While revisions to the regulation are still underway, readers will benefit from the assessment of its current status and anticipated developments.
Categories: Biologics and biotechnology, Drugs, Clinical, Features, Europe, EMA, EC
Tags: Clinical Trial Regulation, EU No 536/2014
Amendments to the 21st Century Cures Act: Changing the Regulation of Combination Products
This article summarizes regulatory changes impacting how premarket applications for combination products will be reviewed by FDA and procedures and reporting requirements for applicants and FDA as required by the 21st Century Cures Act.
Categories: Biologics and biotechnology, Combination products, Drugs, Medical Devices, Features, US, FDA
Tags: 21st Century Cures Act, Combination Products, Primary Mode of Action, PMOA
Strategies Adopted by Innovator Companies in Response to Biosimilars Competition
This article examines key strategies being adopted by the innovator companies and discusses the impact these strategies are likely to have on the future market for biosimilars.
Categories: Biologics and biotechnology, Government affairs, Regulatory strategy, Submission and registration, Features, US, Europe, FDA, EMA
Tags: Biosimilars, Intellectual Property, Litigation, Patent Extension
Biosimilar Intellectual Property Issues in the US: An Update
This article provides an update on US biosimilar intellectual property issues in areas including the complex and evolving areas of patent protection, market exclusivity, the 'patent dance,' and lifecycle planning.
Categories: Biologics and biotechnology, Submission and registration, Features, US, FDA
EU and US Regulations for Chemical Components in Medical Devices
This article discusses a number of regulations directed at the use of chemical components in medical devices, both in the EU and US. The author reviews legislation, offers compliance advice and warns about the penalties of noncompliance.
Categories: Medical Devices, Compliance, Features, US, Europe, FDA, EC
Tags: Chemical Components, Restricted Substances
Drug Regulatory Authority of Pakistan: Organizational Structure, Functions and Future Challenges
This article discusses the development of a more effective pharmaceutical regulatory environment in Pakistan through the establishment of a regulatory agency designed to address current good manufacturing practices and quality management systems for drug production to improve the availability, accessibility and affordability of drugs.
Categories: Drugs, Compliance, Quality, Submission and registration, Features
Tags: DRAP, Drug Regulatory Authority of Pakistan